Evidence map›Paper›PMID 26829187›Full record

ReviewJournal of aerosol medicine and pulmonary drug delivery2016

Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.

Chantal Darquenne, John S Fleming, Ira Katz, Andrew R Martin, Jeffry Schroeter, Omar S Usmani, Jose Venegas, Otmar Schmid

Open access · greenAbstract readReview
In one paragraph

Review in Journal of aerosol medicine and pulmonary drug delivery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 84 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Journal of aerosol medicine and pulmonary drug delivery · 2023
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Feasibility of Aerosolized Alpha-1 Antitrypsin as a Therapeutic Option.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Chantal Darquenne1 Department of Medicine, University of California , San Diego, La Jolla, California.
John S Fleming2 National Institute of Health Research Biomedical Research Unit in Respiratory Disease , Southampton, United Kingdom .
Ira Katz4 Medical R&D, Air Liquide Santé International, Centre de Recherche Paris-Saclay , Jouy-en-Josas, France .
Andrew R Martin6 Department of Mechanical Engineering, University of Alberta , Edmonton, Alberta, Canada .
Jeffry Schroeter7 Applied Research Associates, Inc. , Raleigh, North Carolina.
Omar S Usmani8 Airway Disease Section, National Heart and Lung Institute , Imperial College London and Royal Brompton Hospital, London, United Kingdom .
Jose Venegas9 Department of Anesthesia (Bioengineering), MGH/Harvard, Boston, Massachusetts.
Otmar Schmid10 Comprehensive Pneumology Center (CPC), Member of the German Center for Lung Research , Munich, Germany .
Applied Research Associates (United States) · USLafayette College · USNational Institutes of Health · USNIHR Southampton Respiratory Biomedical Research Unit · GBUniversity of Alberta · CAUniversity of California, San Diego · US

Funding

3D IMAGING &COMPUTER MODEL OF THE RESPIRATORY TRACTR01HL073598 · NHLBI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI CORLEY, RICHARD A · 2004 to 2014
$17.6M
Department of Health CDF-2011-04-053NHLBI NIH HHS R01 HL073598
6 · The paper itself

Abstract

Development of a new drug for the treatment of lung disease is a complex and time consuming process involving numerous disciplines of basic and applied sciences. During the 2015 Congress of the International Society for Aerosols in Medicine, a group of experts including aerosol scientists, physiologists, modelers, imagers, and clinicians participated in a workshop aiming at bridging the gap between basic research and clinical efficacy of inhaled drugs. This publication summarizes the current consensus on the topic. It begins with a short description of basic concepts of aerosol transport and a discussion on targeting strategies of inhaled aerosols to the lungs. It is followed by a description of both computational and biological lung models, and the use of imaging techniques to determine aerosol deposition distribution (ADD) in the lung. Finally, the importance of ADD to clinical efficacy is discussed. Several gaps were identified between basic science and clinical efficacy. One gap between scientific research aimed at predicting, controlling, and measuring ADD and the clinical use of inhaled aerosols is the considerable challenge of obtaining, in a single study, accurate information describing the optimal lung regions to be targeted, the effectiveness of targeting determined from ADD, and some measure of the drug's effectiveness. Other identified gaps were the language and methodology barriers that exist among disciplines, along with the significant regulatory hurdles that need to be overcome for novel drugs and/or therapies to reach the marketplace and benefit the patient. Despite these gaps, much progress has been made in recent years to improve clinical efficacy of inhaled drugs. Also, the recent efforts by many funding agencies and industry to support multidisciplinary networks including basic science researchers, R&D scientists, and clinicians will go a long way to further reduce the gap between science and clinical efficacy.

Indexed as

Biomedical ResearchLungModels, AnatomicPharmaceutical PreparationsRespirationAdministration, InhalationAerosolsConsensusDrug CompoundingHumansImage Interpretation, Computer-AssistedParticle SizeAerosolsPharmaceutical Preparationsaerosol deposition distributionbiological lung modelsin-silico lung modelingPETSPECT

Identifiers

PMID26829187
PMCPMC4841911
OpenAlexW2253113819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.